This is an antibiotic intervention study to determine the value of using
piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae
colonization and infection.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam